Re-evaluation Note REV2021-03, Pest Management Regulatory Agency Re-evaluation and Special Review Work Plan 2021-2026
Pest Management Regulatory Agency
22 June 2021
ISSN: 1925-0649 (PDF version)
Catalogue number: H113-5/2021-3E-PDF
Table of contents
- Background
- Part A - Current re-evaluation and special review work plan (Tables 1-5)
- Part A, Table 1 Targets for consultation and final decisions for legacy active ingredients
- Part A, Table 2 Targets for consultation and final decisions of special reviews
- Part A, Table 3a Targets for consultation and final decisions of cyclical active ingredients (currently under review)
- Part A, Table 3b Status of other active ingredients (currently delayed)
- Re-evaluations initiated between 1 April 2020 and 31 March 2021
- Part B - Future re-evaluation initiations (Table 1)
Background
The purpose of this document is to inform registrants, pesticide regulatory officials and the Canadian public of the re-evaluation and special review work planned by Health Canada's Pest Management Regulatory Agency (PMRA) from 1 April 2021 to 31 March 2026.
This work plan includes the proposed and final decisions published since 1 April 2021, all open re-evaluations and special reviews, as well as new re-evaluations expected to be initiated in this time frame (1 April 2021 to 31 March 2026). This document presents updates to the information last published in Re-evaluation Note REV2020-01, Pest Management Regulatory Agency Re-evaluation and Special Review Work Plan 2020-2025.
Health Canada regulates pesticides in Canada, with the primary objective of protecting the health of Canadians and the environment. A pesticide may only be sold or used in Canada if it has been registered or otherwise authorized under the authority of the Pest Control Products Act. Health Canada uses a rigorous science-based risk assessment approach to ensure that the product meets health and environmental protection standards and has value.
As part of the post-market program, registered pesticides are re-evaluated on a cyclical basis to determine their continued acceptability. Pesticides may also be re-evaluated as a result of changes in the information required or the procedures used by Health Canada to determine that the pesticide meets current health, environment and value standards. The re-evaluation process is described in Regulatory Directive DIR2016-04, Management of Pesticides Re- evaluation Policy. In addition, a special review may be initiated at any time if there are reasonable grounds to believe that the health or environmental risks, or the value of a pesticide, are no longer acceptable. Special reviews differ from re-evaluation in that a special review is intended to examine only specific aspects of a pesticide. Additional information on special reviews can be found in the Guidance Document, Approach to Special Reviews of Pesticides.
Health Canada publishes all post-market proposed decisions for public consultation. Following consultation, comments and information submitted by the public and other stakeholders are considered before Health Canada issues a final decision. Stakeholders are encouraged to stay informed of upcoming consultations, and new initiations, for active ingredients by visiting the Pesticides section of Canada.ca (canada.ca/pesticides).
This five-year work plan may change in response to workload and emerging issues that require priority action. While this work plan will be updated annually, during the course of the year interested stakeholders can monitor the PMRA's Public Registry to view the announcement of new re-evaluations and special reviews, as well as the publication of proposed and final decisions.
Part A - Current re-evaluation and special review work plan (Tables 1-5)
The post-market review program workload is significant, surpassing existing resources and increasing. In response, Health Canada is developing new approaches for pesticide evaluations that will support a sustainable program that makes timely science-based decisions. As part of program renewal, Health Canada is implementing several initiatives to manage the post-market workload such as a risk-based prioritization of re-evaluations.
Re-evaluations for the remaining legacy pesticides; that is, older pesticide active ingredients registered before 1995, older cyclical re-evaluations, and certain neonicotinoid reviews as well as older special reviews, continue to be prioritized for completion. In recent years, as Health Canada has focussed its resources on the review of these priority chemicals, reviews of many of the cyclical re-evaluations were paused. For improved transparency, the work plan identifies the re-evaluations and special reviews that are actively worked on, and those that are delayed. As resources become available, these reviews will resume, and timelines of these re-evaluations will be reflected in future work plans.
As the number of re-evaluation initiations required by the Pest Control Products Act continues to be high, beginning in 2019-2020, Health Canada implemented a risk-based triaging framework to prioritize the scoping and review phases of newer re-evaluation initiations to manage higher risks in a timely manner, and to manage workload efficiently. While new initiations are divided into higher priority or lower priority groupings based on this risk-based prioritization framework, all active ingredients initiated for re-evaluation will continue to be subject to the requirements of the Pest Control Products Act. In addition, beginning in April 2021, Health Canada introduced several measures to help streamline the processing of these newer initiations to help minimize the growing backlog.
Health Canada has made every effort to minimize the impact of the COVID-19 pandemic on regular operations, including the redeployment of resources from the pesticide review program to support other critical Government activities. Also, the delay in publication of decision documents due to the shift in departmental priorities to COVID-19 communications is expected to continue.
The anticipated publication dates outlined in the work plan represent the most up-to-date information on the status of the re-evaluations or special reviews.
Part A, Table 1 Targets for consultation and final decisions for legacy active ingredients
| Active ingredients registered before 1995 | |
|---|---|
| Active ingredient name | Date of final decision |
| Chlorothalonil (paints, coatings and related uses) |
December 2021 |
| Dazomet (paints, coatings and related uses) |
December 2021 |
| Folpet (paints, coatings and related uses) |
December 2021 |
| Piperonyl butoxide | October 2022 |
| Pyrethrins | October 2022 |
| Ziram (paints, coatings and related uses) |
December 2021 |
| Neonicotinoid active ingredients | |
| Active ingredient name | Date of consultation |
| Clothianidin (special review squash bees) |
June 2021 |
| Imidacloprid (special review squash bees) |
June 2021 |
| Thiamethoxam (special review squash bees) |
June 2021 |
| Active ingredient name | Date of final decision |
| Imidacloprid (general re-evaluation) |
Published on 19 May 2021 |
| Older cyclical re-evaluations and special reviews | |
| Active ingredient name | Date of consultation |
| Atrazine (special review) | March 2022 |
| Active ingredient name | Date of final decision |
| Cyromazine | September 2021 |
Diodofon (special review) |
December 2021 |
| Lambda-cyhalothrin | Published on 29 April 2021 |
| Naled (two special reviews) | August 2021 |
| Pentachlorophenol (special review) | November 2021 |
Sodium omadine |
December 2021 |
Part A, Table 2 Targets for consultation and final decisions of special reviews
| Active ingredient name | Date of consultation Footnote 1 |
|---|---|
| Chlorothalonil | November 2021 |
| Dicamba | Q1 (2023-24) |
| Glufosinate ammonium | Q3 (2023-24) |
| Methyl bromide | Q2 (2022-23) |
| Picoxystrobin | Q3 (2022-23) |
| Potassium dimethyldithiocarbamate | Q1 (2022-23) |
| Sodium dimethyldithiocarbamate | Q1 (2022-23) |
| Active ingredient name | Date of final decision Footnote 1 |
| Iprodione | August 2021 |
|
|
Part A, Table 3a Targets for consultation and final decisions of cyclical active ingredients (currently under review)
| Active ingredient name | Re-evaluation category | Date of consultation Footnote 1 |
|---|---|---|
| 1- or 3-Monomethylol-5,5-dimethylhydantoin | 1 | January 2022 |
| 1,3-Bis(hydroxymethyl) -5,5-dimethylhydantoin | 1 | January 2022 |
| 1-Methylcyclopropene | 3 | February 2022 |
| Abamectin | 1 | February 2022 |
| Acetamiprid | 1 | Q4 (2022-23) |
| Ancymidol | 3 | September 2021 |
| Azoxystrobin |
1 | Q2 (2022-23) |
Bacillus subtilis cluster:
|
3 | Q1 (2022-23) |
| Chondrostereum purpureum (Strain: PFC2139) | 3 | January 2022 |
| Clothianidin general re-evaluation Footnote 2 | 1 | Q1 (2023-24) |
| Corn gluten meal | 3 | February 2022 |
| D-cis, trans-allethrin | 1 | Q1 (2023-24) |
| DEET plus related active toluamides | 1 | Q2 (2022-23) |
| Difenoconazole | 2 | Published on 28 May 2021 |
| Dodecylguanidine hydrochloride | 1 | February 2022 |
| Dried blood | 3 | September 2021 |
Enoic acid cluster:
|
3 | October 2021 |
Fatty Acid cluster:
|
3 | Q1 (2022-23) |
| Fenbuconazole | 1 | Q4 (2022-23) |
| Flucarbazone (present as flucarbazone-sodium) | 1 | October 2021 |
| Glufosinate ammonium Footnote * | 1 | Q3 (2023-24) |
| Imiprothrin | 3 | All end use products discontinued. Re-evaluation closed |
| Kaolin | 3 | November 2021 |
| Methyl bromide Footnote * | 1 | Q2 (2022-23) |
Mustard cluster:
|
3 | July 2021 |
Pheromones cluster:
|
3 | May 2021 |
| P-menthane-3,8-diol | 1 | October 2021 |
Predacide cluster: Footnote 3
|
2 | March 2022 |
| Quizalofop-p-ethyl | 1 | Q1 (2022-23) |
| S-metolachlor and R-enantiomer | 1 | March 2022 |
Silicon dioxide cluster:
|
3 | Q1 (2022-23) |
| Tebuconazole | 1 | July 2021 |
| Thiamethoxam general re-evaluation Footnote 2 | 1 | Q1 (2023-24) |
| (Z)-9-Tricosene | 3 | Q1 (2022-23) |
| Trinexapac-ethyl | 1 | November 2021 |
| Triticonazole | 1 | Published on 30 March 2021 |
| Zoxamide | 1 | January 2022 |
| Cumulative Health Risk Assessment: N-methyl carbamates Footnote 4 | 1 | Q1 (2023-24) |
| Active ingredient name | Re-evaluation category | Date of final decision |
| Cymoxanil | 1 | September 2021 |
| Isoxaflutole | 1 | Will be included in the upcoming workplan (Consultation closed in April 2021) |
| Florasulam | 1 | Will be included in the upcoming workplan (Consultation closed in May 2021) |
| Flufenacet | 1 | Will be included in the upcoming workplan (Consultation closed in April 2021) |
| Kresoxim-methyl | 1 | June 2021 |
| S-kinoprene | 1 | June 2021 |
|
||
Part A, Table 3b Status of other active ingredients (currently delayed)
To direct resources for the work (reviews and publication phases) on active ingredients in Tables 1-3a, the re-evaluations of the following active ingredients are delayed. As resources become available, work on these active ingredients will resume and Health Canada will provide an updated status in the next work plan to be published in spring 2022.
| Active ingredient name | Re-evaluation category | Status (at point of delay) |
|---|---|---|
| 4,5-Dichloro-2-N-Octyl-3(2H)-Isothiazolone | 1 | Information gathering phase This active will be clustered with antimicrobial cluster (Table 5) |
| Boscalid | 1 | Scoping phase |
| Cyprodinil | 1 | Review phase |
| Difethialone | 3 | Review phase This active ingredient will be clustered with other rodenticides (Table 5) |
| Famoxadone | 1 | Review phase |
| Fenamidone | 1 | Review phase |
| Fluazinam | 1 | Scoping phase |
| Foramsulfuron | 1 | Information gathering phase |
| Iodosulfuron-methyl-sodium | - | Scoping phase |
Mecoprop cluster:
|
1 | Scoping phase |
| Picolinafen | - | Scoping phase |
| Pymetrozine | 1 | Information gathering phase |
| Pyraclostrobin | 1 | Information gathering phase |
| Spinetoram and Spinosad | 1 | Information gathering phase |
| Trifloxystrobin | 1 | Scoping phase |
Re-evaluations initiated between 1 April 2020 and 31 March 2021
As noted above, the number of re-evaluation initiations currently required as per the 15-year legislative requirement continues to be high. Therefore, Health Canada is maintaining its risk-based triaging and prioritization framework for conducting the scoping and re-evaluation reviews of newer cyclical re-evaluation initiations to manage risks in a timely manner, and to help manage workload efficiently. This prioritization is based on various considerations such as the nature and outcome of existing assessments and overall human health and environmental risk profile, other health and environmental concerns such as information from incident reports received by Health Canada and status in other jurisdictions (for example, decisions from other Organisation for Economic Co-operation and Development member countries), use pattern, sales and use information, knowledge of new information, new data requirements, and, possible clustering of reviews of related active ingredients. Based on the above considerations, a weight-of-evidence approach is taken for prioritization, and Health Canada has grouped the active ingredients into higher priority and lower priority active ingredients for the scoping and review phases. The outcome of scoping reviews will further inform the prioritization of active ingredients for the review phase. All active ingredients initiated for re-evaluation will be subject to the various steps of re-evaluation before making a final re-evaluation decision (in other words, scoping, additional information request when needed, scientific review, public consultation and final decision) as per the Regulatory Directive DIR2016-04, Management of Pesticides Re-evaluation Policy. However, given current capacity considerations, the active ingredients identified as higher priority based on the above factors will be considered first. In some cases, lower priority re-evaluations that can be completed with minimal effort and resources are also considered.
Beginning in April 2021, Health Canada introduced several measures to streamline the processing of the newer initiations to focus on addressing risk concerns, improve timeliness of decisions, and to minimize re-evaluation backlog.
For lower priority active ingredients, a data list of available studies will no longer be requested at initiation. The study list and additional information may be requested, if necessary, once the review of the active ingredient is ready to proceed. Registrants, however, are required to meet their obligations under paragraph 2(f) Pest Control Products Incident Reporting Regulations (https://laws-lois.justice.gc.ca/eng/regulations/SOR-2006-260/page-1.html#h-725576), which indicates: registrants must provide a scientific study they have sponsored if it indicates either a new health or environmental hazard, increased health or environmental risk or the presence of a component or derivative that has not been previously detected. These studies must be submitted to PMRA according to the timelines outlined in the Incident Reporting Regulations. Failure to do so may be subject to regulatory action. Further, a streamlined approach will be considered; for example, scientific assessments of lower priority active ingredients will not be updated unless necessary, PMRA's efforts and resources will focus on the higher priority active ingredients.
For higher priority active ingredients, in addition to providing the data list of available scientific studies at initiation, registrants are required to provide an executive summary of each of the studies listed. These summaries will provide pertinent information about the study methodology and results, which will inform Health Canada in determining the relevance of the study, and to determine data requirements during the scoping and review phases.
Resources will continue to focus on the risk profile of the active ingredient, ensuring that the level of effort is commensurate with the risk. Thus, comprehensive new evaluations and requests for additional information/scientific studies will only be conducted if necessary to address the risks of concern.
For the active ingredients initiated for re-evaluation between 1April 2020 and 31 March 2021, the prioritization exercise described above has been completed. The higher and lower priority groupings are outlined in Table 4 along with the current status in the re-evaluation process.
As resources become available, scoping of the active ingredients in Table 4 will be completed, and the status will be updated in the next upcoming work plan (2022-2027), planned to be published in spring 2022.
Part A, Table 4 Status of re-evaluations initiated between 1 April 2020 and 31 March 2021
| Active ingredient name | Status |
|---|---|
| Higher priority | |
| 1,2-Dibromo-2,4-Dicyanobutane | Scoping phase |
| 10,10'-Oxybis(Phenoxarsine) | Scoping phase |
| Bensulide | Scoping phase |
| Bifenazate | Scoping phase |
| Coumaphos | All products discontinued, re-evaluation closed |
| Daminozide | Scoping phase |
Fish toxicants cluster:
|
Scoping phase |
| Hydramethylnon | All products discontinued, re-evaluation closed |
| Ipconazole | Scoping phase |
| Methoxyfenozide | Scoping phase |
| Mesotrione | Scoping phase |
| Phorate | Scoping phase |
|
See Table 3a |
| Tepraloxydim | All products discontinued, re-evaluation closed |
| Tetrachlorvinphos | Scoping phase |
| Lower priority | |
| 1-Methylcyclopropene | See Table 3a |
| 2-Bromo-4'-Hydroxyacetophenone | All products discontinued, re-evaluation closed |
Bacillus subtilis cluster :
|
See Table 3a |
Capsaicin cluster:
|
Scoping phase |
| Chondrostereum purpureum (Strain: PFC2139) | See Table 3a |
Fatty acid cluster:
|
See Table 3a |
| Kaolin | See Table 3a |
| Methyl Nonyl Ketone | Scoping phase |
| Nonylphenoxypolyethoxyethanol (adjuvant) | Scoping phase |
Silicon dioxide cluster:
|
See Table 3a |
| Sulphur | Scoping phase |
Part A, Table 5 Re-evaluations to be initiated between 1 April 2021 and 31 March 2022
In accordance with the Pest Control Products Act, the active ingredients listed in Table 5 must be initiated between 1 April 2021 and 21 March 2022 depending on the initial registration date, or the date of the last completed re-evaluation. Information related to the re-evaluation initiation will be posted to the PMRA's Public Registry. Risk-based triaging and prioritization will be applied.
| Active ingredient | Status |
|---|---|
| 2021-2022 | |
| 1-(3-Chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride (cis isomer) | Initiated in April 2021 |
| Bis(Trichloromethyl)Sulfone | Initiated in April 2021 |
| 2-(Hydroxymethyl)-2-nitro-1,3-propanediol | Initiated in May 2021 |
Antimicrobials cluster:
|
To be initiated October 2021-March 2022 |
| 4-CPA (4-chlorophenoxyacetic acid) | To be initiated March 2022 |
| 6-Benzylaminopurine | To be initiated February 2022 |
| Aminopyralid | To be initiated February 2022 |
Hypochlorite cluster:
|
To be initiated June 2021 |
Triazinetrione cluster:
|
To be initiated October 2021-March 2022 |
| Bacillus sphaericus | Initiated in May 2021 |
Rodenticide cluster:
|
To be initiated March 2022 |
| Bromacil (present in free form, as dimethylamine salt, or as lithium salt) | To be initiated March 2022 |
Carbon dioxide cluster:
|
To be initiated July 2022 |
| Cyazofamid | To be initiated October 2021 |
| Dichlobenil | To be initiated March 2022 |
| Diflubenzuron | To be initiated March 2022 |
| Formic acid | Initiated in May 2021 |
Gibberellins cluster:
|
To be initiated February 2022 |
| Metribuzin | To be initiated March 2022 |
Nucleopolyhedrovirus cluster:
|
To be initiated March 2022 |
| Paraquat | To be initiated March 2022 |
| Pinoxaden | To be initiated October 2021 |
| Polymerized butenes | To be initiated January 2022 |
| Potassium bicarbonate | Initiated in May 2021 |
| Prohexadione calcium | Initiated in April 2021 |
| Putrescent whole egg solids | Initiated in May 2021 |
| Pyrimethanil | To be initiated August 2021 |
| Spirodiclofen | Initiated in May 2021 |
| Terbacil | To be initiated February 2022 |
| Topramezone | To be initiated November 2021 |
| Triclopyr (present as butoxyethyl ester) | To be initiated February 2022 |
| Verbenone | To be initiated March 2022 |
Part B - Future re-evaluation initiations (Table 1)
In general, the initiation date of the re-evaluation of a particular active ingredient is based on the date of its initial registration, or the date of the last completed re-evaluation. A complete list of all re-evaluation initiations anticipated between April 2022 and March 2026 is included in Table 1.
Part B, Table 1 Future re-evaluation initiations between 1 April 2022 and 31 March 2026
| Active ingredient | |
|---|---|
| 1 April 2022 to 31 March 2023 | |
| Acifluorfen (present as sodium salt) | Natamycin |
| Agrobacterium radiobacter | Novaluron |
| Carbendazim | Octenol |
| Carfentrazone-ethyl | Oxadiazon |
| Di-n-propyl isocinchomeronate | Oxyfluorfen |
Dioxaborinanes cluster:
|
Pantoea agglomerans cluster:
|
| Diphenylamine | Prothioconazole |
Endothal cluster:
|
Pyrasulfotole |
| Etridiazole | Sodium chloride |
| Fluvalinate-tau | Spiromesifen |
| Naled | Sulfuryl fluoride |
| 1 April 2023 to 31 March 2024 | |
| 3-Methyl-2-cyclohexen-1-one | German cockroach extract |
| Acequinocyl | Metalaxyl cluster:
|
| Ammonium bromide | Napropamide |
| Atrazine (plus related active triazines) | Oxamyl |
| Bentazon (present as sodium salt) | Prometryne plus related active triazines |
| Bispyribac-sodium (KIH-2023) | Pyroxsulam |
| Cellulose (from powdered corn cobs) | Rotenone |
| Chlorpropham | (S)-Methoprene |
| Clomazone | Sethoxydim |
| Didecyldimethylammonium (present as carbonate and bicarbonate salts) | Streptomyces lydicus strain WYEC108 |
| Diuron | Sulfonyl ureas cluster:
|
| EPTC | Thiacloprid |
| Fenbutatin oxide | Triallate |
| Ferric sodium ethylenediaminetetraacetic acid | |
| 1 April 2024 to 31 March 2025 | |
| 1,2-Benzisothiazolin-3-one | MCPA cluster:
|
2,4-D cluster:
|
Metaldehyde |
2-Phenylphenol and Salts cluster:
|
Metarhizium anisopliae Strain F52 |
Alkyl Dimethyl Benzyl Ammonium Chloride Cluster (ADBAC):
|
Mineral Oil |
Bacillus thuringiensis cluster:
|
Mono- and Di-Potassium Salt of Phosphorous Acid |
| Beauveria bassiana Strain HF23 | Naphthalene Acetic Acid (Present as Ethyl Ester, Sodium Salt, or as Ammonium Salt) |
| Bromoxynil | Oxirane Derivatives - 50% Minimum |
| Chlorantraniliprole | Ozone |
| Chlorthal (Present as Dimethyl Ester) | Picloram cluster:
|
| Coniothyrium minitans Strain CON/M/91-08 | Pendimethalin |
| Cyprosulfamide | Propylene Glycol |
| Dicamba (Present as Acid, Amine Salt, Ester, Potassium Salt, or Sodium Salt) | Pyrazon |
Didecyl Dimethyl Ammonium Chloride Cluster (DDAC):
|
Industrial Uses of Sodium Chlorite and Sodium Chlorate cluster:
|
| Dodine | Spirotetramat |
| Ethofumesate | Streptomycin |
| Flumioxazin | Sulfentrazone |
| Gliocladium catenulatum | Tetrakishydroxymethyl Phosphonium Sulphate |
| Glutaraldehyde | Thiencarbazone-Methyl |
| Imazapyr | - |
| Maleic Hydrazide | - |
| Mandipropamid | - |
| 1 April 2025 to 31 March 2026 | |
| Beauveria Bassiana Strain Gha |
|
| Bifenthrin | Nosema Locustae Canning, (Spore Of) |
| Carbathiin | Oxycarboxin |
| Chlormequat Chloride | Phenmedipham |
| Desmedipham | Propyzamide |
| Diazinon | Pseudomonas Fluorescens A506 |
| Dimethenamid-P | Tribenuron-Methyl |
| Dithiopyr | Trifluralin |
| Formetanate Hydrochloride | R-(-)-1-Octen-3-Ol |
| Hexazinone | Saflufenacil |
| Imazamethabenz-Methyl | Simazine Plus Related Active Triazines |
| Lime Sulphur Or Calcium Polysulphide | Verticillium Albo-Atrum, Isolate Wcs850 |
N-Coco-Alkyltrimethylene Diamines Present As:
|
- |
Page details
- Date modified: